| 1 |
22664478 | Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib). | 2013 Oct |
1 |
| 2 |
23508585 | PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma. | 2013 Dec |
2 |
| 3 |
21464406 | Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma. | 2011 May 20 |
1 |
| 4 |
19945857 | EORTC study 26041-22041: phase I/II study on concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) with PTK787/ZK222584 (PTK/ZK) in newly diagnosed glioblastoma. | 2010 Jan |
2 |
| 5 |
20091169 | A phase I dose escalation and pharmacokinetic study of vatalanib (PTK787/ZK 222584) in combination with paclitaxel in patients with advanced solid tumors. | 2010 Aug |
1 |
| 6 |
20682704 | Biological evidence for dual antiangiogenic-antiaromatase activity of the VEGFR inhibitor PTK787/ZK222584 in vivo. | 2010 Aug 15 |
2 |
| 7 |
19411318 | Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer. | 2009 May |
1 |
| 8 |
19668241 | Therapeutic targeting of the PDGF and TGF-beta-signaling pathways in hepatic stellate cells by PTK787/ZK22258. | 2009 Oct |
1 |
| 9 |
17698976 | Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. | 2008 Jan |
1 |